Babesiosis Data Readout Today As 60 Degrees Pharmaceuticals Shares Climb

60 Degrees Pharmaceuticals (SXTP) reported negative PCR results in 5 patients from its expanded access study of tafenoquine for babesiosis, with 4 also testing negative on a sensitive NAT test. All patients showed clinical improvement. The stock is down 29% to $0.60. The company expects to unblind a separate study in January 2027. Tafenoquine is not FDA-approved for babesiosis.

60 Degrees Pharmaceuticals (SXTP) reported clinical improvement and negative PCR results in all five patients completing its babesiosis study. 80% also tested negative on a sensitive assay. Two more patients are ongoing, with enrollment at seven. The company plans to unblind a separate study in January 2027 and seek FDA pre-approval discussions.

60 Degrees Pharmaceuticals (SXTP) reported that all 5 completed patients in its expanded access study showed clinical improvement and tested negative for Babesia via PCR, with 4/5 also NAT-negative post-treatment. The company may seek accelerated FDA approval using NAT nonreactivity as a surrogate. Two additional patients are currently being treated, with a total enrollment of 7. The study remains open pending potential FDA discussions.

60 Degrees Pharmaceuticals reported that all five patients in its expanded access study for relapsing babesiosis showed significant improvement and tested negative for the parasite. Four of five patients also tested negative on highly sensitive NAT testing. The study evaluates tafenoquine-containing regimens and remains open with seven patients enrolled. The company plans to discuss potential FDA approval pathways.

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients ● All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on

60 Degrees Pharmaceuticals (SXTP) updated investors on tafenoquine for babesiosis, noting a blinded study to unblind in January 2027, three confirmed cures, and a potential 2027 FDA filing. Early chronic-study screening showed genus-level signals in 2 of 9 patients, but no positive B. microti results.